Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Tel Aviv
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Redhill Biopharma Ltd

+ Add to Watchlist

RDHL:IT

616.50 ILs 1.20 0.20%

As of 10:39:30 ET on 05/28/2015.

Snapshot for Redhill Biopharma Ltd (RDHL)

Open: 604.00 Day's Range: 604.00 - 619.90 Volume: 43,558
Previous Close: 615.30 52wk Range: 295.00 - 680.00 1-Yr Rtn: +5.38%

Stock Chart for RDHL

No chart data available.
  • RDHL:IT 615.80
  • 1D
  • 1M
  • 1Y
615.30
Interactive RDHL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RDHL

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. TA-100 -
Earnings Per Share (USD) (ttm) -0.2110
Est. EPS (USD) (12/2015) -
Est. PEG Ratio -
Market Cap (M ILS) 612.70
Shares Outstanding (M) 99.38
30 Day Average Volume 111,384
Price/Book (mrq) 5.5956
Price/Sale (ttm) 14,038.2705
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/22/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RDHL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RDHL

Redhill Biopharma Ltd focuses primarily on the development and acquisition of therapeutic candidates acquired through asset purchases or in-licensing. The Company acquires, in-licenses and develops patent-protected new formulations and combinations of existing drugs in advanced stages of development.

Dror Ben-AsherChairman/CEOOri ShiloDpty CEO:Finance & Operations
Uri Hananel AharonChief Accounting OfficerGuy GoldbergChief Business Officer
More Company Profile & Key Executives for RDHL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil